Securities Report - 70th Fiscal Period (2025/04/01 - 2026/03/31)

Toho Pharmaceutical Co., Ltd. Securities Report - 70th Fiscal Period (2025/04/01 - 2026/03/31)

Toho Pharmaceutical Co., Ltd. has submitted its Securities Report for the 70th fiscal period (April 1, 2025 to March 31, 2026) to the Financial Services Agency. This report provides detailed information on the company's financial performance, financial position, earnings forecasts, and future management strategies.

The company continues to focus on the development, manufacturing, and marketing of prescription and over-the-counter pharmaceuticals. It is particularly strengthening its presence in therapeutic areas such as chronic diseases and central nervous system disorders. To meet evolving healthcare demands domestically and internationally, the company is maintaining consistent investment in research and development, advancing clinical trials for next-generation drug candidates.

Financially, the company maintains a stable revenue base and continues its shareholder return policy through regular dividend payments. It is also prioritizing the reinforcement of its holding company structure and promoting sustainable management, with enhanced initiatives related to environmental, social, and governance (ESG) factors.

Looking ahead, the company has identified accelerated global expansion, integration with digital health technologies, and AI-driven efficiency in drug discovery as key pillars of its growth strategy, aiming for long-term corporate value enhancement. This report is published as part of the company's commitment to transparency and reliable disclosure to investors and stakeholders.